Abstract
Mineralocorticoid receptor (MR) blockers attenuate cardiac remodeling in experimental models of heart failure, myocardial infarction and pressure-overload, in which the renin-angiotensin-aldosterone system is activated. Mice lacking the gene encoding guanylyl cyclase-A (GC-A), a common receptor for atrial and brain natriuretic peptide (ANP and BNP, respectively), show marked cardiac hypertrophy and fibrosis, which are almost completely inhibited by both genetic and pharmacological blockade of type 1 angiotensin II receptors. However, the effect of eplerenone, a specific MR blocker, on cardiac remodeling in GC-A knockout (GC-A KO) mice remains unknown. Male 12-week-old GC-A KO mice were assigned to control, eplerenone and hydralazine groups (n=6–7/group). Treatment with eplerenone at a dose of 100 mg/kg body weight/d reduced heart weight/body weight ratios, interstitial fibrosis and blood pressure to levels similar to those seen in wild type mice, in association with reduced transcription of atrial natriuretic peptide, brain natriuretic peptide, transforming growth factor-β1, collagen I and collagen III. Although hydralazine (5 mg/kg body weight/d) exerted a similar effect on blood pressure, it did not inhibit the cardiac remodeling in GC-A KO mice. In conclusion, eplerenone attenuates cardiac remodeling in GC-A KO mice, most likely in a blood pressure-independent manner, which suggests that signaling downstream of MR is involved in the ventricular remodeling of GC-A KO mice.
Similar content being viewed by others
Article PDF
References
Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
The EPHESUS Investigators : Eplerenone, a selective aldosterone blocker inpatients wth left ventricular dysfunction after acute myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL : Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252–1257.
Urabe A, Izumi T, Abe Y, Taniguchi I, Mochizuki S : Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. Hypertens Res 2006; 29: 627–634.
Kuster GM, Kotlyar E, Rude MK, et al: Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111: 420–427.
Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT : Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355–1364.
Rocha R, Rudolph AE, Frierdich GE, et al: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802–H1810.
Lopez MJ, Wong SK, Kishimoto I, et al: Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995; 378: 65–68.
Oliver PM, Fox JE, Kim R, et al: Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 1997; 94: 14731–14735.
Kishimoto I, Garbers DL : Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms. Curr Opin Nephrol Hypertens 1997; 6: 58–63.
Li Y, Kishimoto I, Saito Y, et al: Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 2002; 106: 1722–1728.
Yoshimura M, Nakamura S, Ito T, et al: Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002; 87: 3936–3940.
Knowles JW, Esposito G, Mao L, et al: Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001; 107: 975–984.
Hirata Y, Tomita M, Yoshimi H, Kuramochi M, Ito K, Ikeda M : Effect of synthetic human atrial natriuretic peptide on aldosterone secretion by dispersed aldosterone-producing adenoma cells in vitro. J Clin Endocrinol Metab 1985; 61: 677–680.
Ito T, Yoshimura M, Nakamura S, et al: Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003; 107: 807–810.
Garnier A, Bendall JK, Fuchs S, et al: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004; 110: 1819–1825.
Nagata K, Obata K, Xu JL, et al: Mineralocorticoid receptor antagonism attenuates cardac hypertrophy and failure I low-aldosterone hypertensive rats. Hypertension 2006; 47: 656–664.
Young M, Fullerton M, Dilley R, Funder J : Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578–2583.
Sato A, Funder JW : High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996; 137: 4145–4153.
Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T : Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralcorticoid receptor. Hypertension 2007; 50: 877–883.
Petez-Rojas JM, Blanco JA, Cruz C, et al: Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292: F131–F139.
Feria I, Pichardo I, Juarez P, et al: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43–52.
Tokudome T, Horio T, Kishimoto I, et al: Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation 2005; 111: 3095–3104.
Franco V, Chen YF, Feng JA, et al: Eplerenone prevents adverse cardiac remodeling induced by pressure overload in atrial natriuretic peptide-null mice. Clin Exp Parmacol Physiol 2006; 33: 773–779.
Suzuki J, Iwai M, Mogi M, et al: Eplereneone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917–921.
Kuwahara F, Kai H, Tokuda K, et al: Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130–135.
Petrov VV, Fagard RH, Lijnen PJ : Stimulation of collagen production by transforming growth factor-β1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002; 39: 258–263.
Oates JA, Brown NJ : Antihypertensive agents and the drug therapy of hypertension, in Hardman JD and Limbird LE (eds): Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp 871–900.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Q., Saito, Y., Naya, N. et al. The Specific Mineralocorticoid Receptor Blocker Eplerenone Attenuates Left Ventricular Remodeling in Mice Lacking the Gene Encoding Guanylyl Cyclase-A. Hypertens Res 31, 1251–1256 (2008). https://doi.org/10.1291/hypres.31.1251
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.31.1251
